A single-center retrospective study assessing the incidence and clinical sequelae of unexpected interruptions (UI) in drug delivery in patients with refractory hypoxemia, right heart failure, and post-cardiac surgery pulmonary hypertension inhaled Epoprostenol via the Aerogen
Latest Information Update: 11 Dec 2020
At a glance
- Drugs Epoprostenol (Primary)
- Indications Hypoxaemia; Pulmonary arterial hypertension; Right ventricular dysfunction
- Focus Adverse reactions
- 11 Dec 2020 New trial record
- 21 Oct 2020 Results presented at the CHEST Annual Meeting 2020 by Annual Meeting of the American College of Chest Physicians